VKH
LAB icon

Virtu KCG Holdings’s Standard BioTools LAB Stock Holding History

Virtu KCG Holdings’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$105K Buy
+25,870
New +$123K ﹤0.01% 2401

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu KCG Holdings's LAB Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Standard BioTools (LAB) in Q2 2017: 25,870 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #2401 among its holdings.

80 funds tracked by Wall St. Rank hold LAB as of Q2 2017.

  • Virtu KCG Holdings held 25,870 shares of Standard BioTools worth $105K as of Q2 2017.
  • Standard BioTools was a new Virtu KCG Holdings position in Q2 2017.
  • Standard BioTools made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2401 holding.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.